

## IMMUNOGENIC COMPOSITION AND METHODS

This invention was supported in part by funds from the United States government (National Institutes of Health, Grant Nos. NIH NO1-AI 05397 and NIH  
5 NO1-AI 25458). The United States government may therefore have certain rights in this invention.

## BACKGROUND OF THE INVENTION

To enhance the efficacy of immunogenic compositions, a variety of  
10 immunogenic compositions and methods have been reported using protein compositions, plasmid-based compositions, and recombinant virus constructs as immunogenic compositions. Prior studies have demonstrated that plasmid-based immunogenic compositions, upon systemic application, prime the systemic immune system to a second systemic immunization with a traditional antigen, such as a  
15 protein or a recombinant virus (See, e.g., Xiang *et al.*, 1997 *Springer Semin. Immunopathol.*, 19:257-268; Schneider, J. *et al.*, 1998 *Nature Med.*, 4:397; and Sedeguh, M. *et al.*, 1998 *Proc. Natl. Acad. Sci., USA*, 95:7648; Rogers, W. O. *et al.*, 2001 *Infect. & Immun.*, 69(9):5565-72; Eo, S. K., *et al.*, 2001 *J. Immunol.*, 166(9):5473-9; Ramshaw I. A. and Ramsay, A. J., 2000 *Immunol. Today*, 21(4):163-  
20 5).

An often used DNA prime/live vector boost regimen involves vaccinia viruses for the boost. Examples in the recent literature include such immunization for human immunodeficiency virus (HIV) (Hanke T. *et al.*, 2002 *Vaccine*. 20(15):1995-8; Amara R.R. *et al.*, 2002 *Vaccine*. 20(15):1949-55; Wee E.G. *et al.*,  
25 2002 *J. Gen. Virol.*, 83(Pt 1):75-80; Amara R.R. *et al.*, 2001 *Science*. 292(5514):69-74). Prime-boost immunizations with DNA and modified vaccinia virus vectors expressing antigens such as herpes simplex virus-2 glycoprotein D, *Leishmania infantum* P36/LACK antigen, *Plasmodium falciparum* TRAP antigen, HIV/SIV antigens, murine tuberculosis antigens, and influenza antigens, have been reported to  
30 elicit specific antibody and cytokine responses (See, e.g., Meseda C.A. *et al.*, 2002 *J. Infect. Dis.*, 186(8):1065-73; Amara R.R. *et al.*, 2002 *J. Virol.*, 76(15):7625-31; Gonzalo R.M. *et al.*, 2002 *Vaccine*, 20(7-8):1226-31; Schneider J. *et al.*, 2001

*Vaccine*, 19(32):4595-602; Hel Z. *et al*, 2001 *J. Immunol.*, 167(12):7180-91; McShane H. *et al*, 2001 *Infec. & Immun.*, 69(2):681-6 and Degano P. *et al* 1999 *Vaccine*, 18(7-8):623-32 influenza and malaria models).

5 Plasmid prime-adenovirus boost genetic immunization regimens have recently been reported to induce alpha-fetoprotein-specific tumor immunity and to protect swine from classical swine fever (See, e.g., Meng W. S. 2001 *Cancer Res.*, 61(24):8782-6; Hammond, J. M. *et al*, 2001 *Vet. Microbio.*, 80(2):101-19; and United States Patent No. 6,210,663).

10 Other DNA plasmid prime-virus boost regimens have been reported. See, e.g., Matano T. *et al*, 2001 *J. Virol.*, 75(23):11891-6 (a DNA prime/Sendai virus vector boost). DNA priming with recombinant poxvirus boosting has been reported for HIV-1 treatment (See, e.g., Kent, S. J. *et al*, 1998 *J. Virol.*, 72:10180-8; Robinson, H. L. *et al*, 1999 *Nat. Med.*, 5:526-34; and Tartaglia, J. *et al*, 1998 *AIDS Res. Human Retrovirus.*, 14:S291-8).

15 While a number of DNA prime/viral boost regimens are being evaluated, currently described immunization regimens have several disadvantages. For example, some of these above-noted viruses cause disease symptoms in subjects; others may result in recombination *in vivo*. Still other viruses are difficult to manufacture and/or have a limited ability to accept foreign genes. Still other viruses  
20 have disadvantages caused by significant pre-existing vector immunity in man, and other safety concerns.

There remains a need in the art for novel and useful immunization regimens that can produce enhanced levels of cellular and humoral immune responses to the antigens in question and meet the requirements of safety, ease of manufacture and the  
25 ability to overcome the mammalian hosts natural immune response to the vectors upon booster immunization.

#### SUMMARY OF THE INVENTION

30 The present invention provides a novel method, composition, and kit for the inducing in a mammalian subject an immune response against a pathogenic antigen or other antigen via a prime/boost regimen that shows a surprising synergistic stimulation of cellular immune response to the antigen compared to results obtained

with either the DNA plasmid component or the recombinant viral component, when administered individually.

In one embodiment, the invention provides a novel method of inducing an antigen-specific immune response in a mammalian subject. The method involves  
5 administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian cell by the DNA plasmid. The method further involves administering to the subject an effective  
10 amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian cell by the rVSV. In one embodiment, the recombinant VSV is an attenuated, replication competent virus. In another embodiment, the recombinant VSV is a non-replicating virus. The administrations of the first and second compositions may be in any order.  
15 Further, the invention contemplates multiple administrations of one of the compositions followed by multiple administrations of the other composition. In one embodiment, a cytokine is preferably co-administered.

In another embodiment the invention provides an immunogenic composition for inducing an antigen-specific immune response to an antigen in a mammalian  
20 subject. The immunogenic composition comprises a first composition comprising a DNA plasmid comprising a DNA sequence encoding the antigen under the control of regulatory sequences directing expression thereof by the DNA plasmid. This composition also includes at least one replication competent, recombinant vesicular stomatitis virus (VSV) comprising a nucleic acid sequence encoding the same  
25 antigen under the control of regulatory sequences directing expression thereof by the recombinant VSV.

In yet another embodiment, the invention provides a kit for use in a therapeutic or prophylactic method of inducing an increased level of antigen-specific immune response in a mammalian subject. The kit includes, *inter alia*, at least one  
30 first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian cell; at least one second composition comprising a replication competent,

recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding said antigen under the control of regulatory sequences directing expression thereof in said mammalian cell; and instructions for practicing the above-recited method.

5 In another embodiment, the invention provides the use of the above-described immunogenic composition or components thereof in the preparation of a medicament for inducing an immune response in an animal to the antigen employed in the composition.

Other aspects and embodiment of the present invention are disclosed in the  
10 following detailed description.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic diagram of an illustrative plasmid DNA encoding a simian immunodeficiency virus (SIV) gag p37 protein. The diagram shows that the  
15 plasmid contains a human cytomegalovirus (HCMV) promoter/enhancer driving expression of the gag protein, a bovine growth hormone polyadenylation site (BGH polyA), an origin of replication sequence (ori) and a kanamycin resistance (*kan<sup>R</sup>*) marker gene.

FIG. 1B is a schematic diagram of an illustrative bicistronic plasmid DNA  
20 encoding the two subunits p35 and p40 of rhesus interleukin 12. The p35 subunit is under the control of the HCMV promoter and has an SV40 poly A site. The p40 subunit is under the control of the simian cytomegalovirus (SCMV) promoter and has a BGH poly A site, and is transcribed in the reverse direction. This plasmid also contains an ori sequence and a *kan<sup>R</sup>* gene.

FIG. 2 is a bar graph showing VSV N-specific gamma interferon (IFN- $\gamma$ )  
25 ELISpot responses in unfractionated peripheral blood mononuclear cells (PBMC) from animals immunized by a prime/boost regimen of the present invention. The leftmost dark bars represent a protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing an influenza hemagglutinin (flu HA) protein. Light gray bars represent a protocol of the invention  
30 involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins. The pale bars represent a protocol

involving a priming immunization with an empty or control DNA plasmid (con DNA) followed by immunization with a VSV expressing the HIV gag and env proteins. The rightmost dark bars represent a protocol involving a priming immunization with con DNA plasmid followed by immunization with a VSV expressing flu HA protein. Each group represents results from 5 animals.

FIG. 3 is a bar graph showing HIVenv 6101-specific gamma interferon (IFN- $\gamma$ ) ELISpot responses in unfractionated PBMC from animals immunized by a prime/boost regimen of the present invention. The leftmost light gray bars represent a protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing flu HA protein. The striped bars represent a protocol of the invention involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins. The checkerboard bars represent a protocol involving a priming immunization with an empty control DNA followed by immunization with a VSV expressing the HIV gag and env proteins. The dotted bars represent a protocol involving a priming immunization with control DNA plasmid followed by immunization with a VSV boost expressing flu HA protein. Each group represents results from 5 animals. The asterisks indicate where statistically significant differences occurred at  $p=0.0001$ .

FIG. 4 is a graph showing serum anti-SIV gag p27 antibody titer by enzyme-linked immunosorbent assay (ELISA) for animals immunized by a prime/boost regimen of the present invention. Plasmid DNA was administered on day 0, week 4 and week 8 and VSV (serotype Indiana G) and VSV (serotype Chandipura G) boosts were administered on week 15 and 23, respectively. A protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing flu HA protein is represented by ( $\diamond$ ). A protocol of the invention involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins is represented by ( $\blacksquare$ ). A protocol involving a priming immunization with an empty control DNA followed by immunization with a VSV expressing the HIV gag and env proteins is represented by ( $\blacktriangle$ ). A protocol involving a priming immunization with control DNA plasmid followed by immunization with a VSV expressing flu HA protein is represented by

(●). Each group represents results from 5 animals. Statistically significant differences between groups are shown as  $p=0.0073$  (\*);  $p=0.5941$  (#) or  $p=0.0027$  (¥).

FIG. 5 is a graph showing SIV gag-specific spot forming cells per million cells evaluated by ELISpot assay for animals immunized by a prime/boost regimen of the present invention. Plasmid DNA was administered on day 0, week 4 and week 8 and VSV (serotype Indiana G) and VSV (serotype Chandipura G) boosts were administered on week 15 and 23, respectively. A protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing flu HA protein is represented by (◆). A protocol of the invention involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins is represented by (■). A protocol involving a priming immunization with an empty control DNA followed by immunization with a VSV expressing the HIV gag and env proteins is represented by (▲). The (●) represent a protocol involving a priming immunization with control DNA plasmid followed by immunization with a VSV expressing flu HA protein. Each group represents results from 5 animals. Statistically significant differences between groups are indicated by brackets for  $p=0.0001$  and  $p=0.0002$ .

FIG. 6 is a graph showing the elevated immune responses elicited by the prime/boost combinations indicated by the same symbols as in Fig. 5 results in increased protection from AIDS, as measured by a decreased loss of CD4 T-cells cells in days after challenge

FIG. 7 is a graph showing the elevated immune responses elicited by the prime/boost combinations indicated by the same symbols as in Fig. 5 results in increased protection from AIDS, as measured by a decrease in circulating virus in plasma (virus copies/ml) in days after challenge.

#### DETAILED DESCRIPTION OF THE INVENTION

The invention provides a novel method of inducing an antigen-specific immune response in a mammalian subject or vertebrate subject by using in combination certain components of immunogenic compositions described in the prior art, and optimizing the components to produce surprising and synergistic results.

Generally, the method involves administering to the subject an effective amount of a composition that includes a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell by the DNA plasmid. The method also includes a step of administering to the subject an effective amount of a composition comprising a replication competent, recombinant vesicular stomatitis virus (rVSV). This rVSV comprises a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell by the rVSV.

The first of these two immunogenic compositions to be administered in order is referred to as the priming composition. The second of these two immunogenic compositions to be administered in order is referred to as the boosting composition. Thus, either the DNA composition may be administered as the priming composition and the VSV vector composition administered as the boosting composition or vice versa. In one embodiment, the priming composition is administered to the subject at least once or multiple times prior to administration of the boosting composition. Thereafter, the boosting composition is subsequently administered to the subject at least once or multiple times. Further the invention contemplates multiple administrations of one of the compositions followed by multiple administrations of the other composition. The method further contemplates administering an effective amount of a cytokine as a step in the method.

It has been surprisingly found that practice of this method induces in a mammalian subject an immune response including an increase in CD8+ T cell response to the antigen greater than that achieved by administering the DNA plasmid or recombinant VSV alone. In fact, as indicated in the examples below, the immune response is greater than that expected by an additive combination of the two immunogenic compositions. Thus, the immune response induced by the novel method is a dramatic and synergistic increase in cellular and/or antibody responses to the antigen. See, e.g., Table 1 below and FIGs. 4 and 5, in which the peak antigen specific cellular response to the HIV-1 gag is over 3-fold higher than the response to administration of a DNA plasmid immunogenic composition alone or almost 9-fold

higher than the response to the administration of the rVSV immunogenic composition alone.

While it is contemplated that the mammalian subject is a primate, preferably a human, the invention is not limited by the identification of the mammalian subject.

- 5 The components of this method are described in detail below and with reference to the cited documents that are incorporated by reference to provide detail known to one of skill in the art.

**A. DNA Plasmid Immunogenic Composition**

- 10 Immunogenic compositions of this invention include a DNA plasmid comprising a DNA sequence encoding a selected antigen to which an immune response is desired. In the plasmid, the selected antigen is under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The components of the plasmid itself are conventional.

- 15 Non-viral, plasmid vectors useful in this invention contain isolated and purified DNA sequences comprising DNA sequences that encode the selected immunogenic antigen. The DNA molecule may be derived from viral or non-viral, e.g., bacterial species that have been designed to encode an exogenous or heterologous nucleic acid sequence. Such plasmids or vectors can include sequences  
20 from viruses or phages. A variety of non-viral vectors are known in the art and may include, without limitation, plasmids, bacterial vectors, bacteriophage vectors, "naked" DNA and DNA condensed with cationic lipids or polymers.

- Examples of bacterial vectors include, but are not limited to, sequences derived from *bacille Calmette Guérin* (BCG), *Salmonella*, *Shigella*, *E. coli*, and  
25 *Listeria*, among others. Suitable plasmid vectors include, for example, pBR322, pBR325, pACYC177, pACYC184, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pK37, pKC101, pAC105, pVA51, pKH47, pUB110, pMB9, pBR325, Col E1, pSC101, pBR313, pML21, RSF2124, pCR1, RP4, pBAD18, and pBR328.

- Examples of suitable inducible *Escherichia coli* expression vectors include  
30 pTrc (Amann *et al.*, 1988 *Gene*, 69:301-315), the arabinose expression vectors (e.g., pBAD18, Guzman *et al.*, 1995 *J. Bacteriol.*, 177:4121-4130), and pETIId (Studier *et al.*, 1990 *Methods in Enzymology*, 185:60-89). Target gene expression from the pTrc



vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pETIIId vector relies on transcription from a T7 *gn10*-lac fusion promoter mediated by a coexpressed viral RNA polymerase T7 *gn1*. This viral polymerase is supplied by host strains BL21 (DE3) or  
5 HMS I 74(DE3) from a resident prophage harboring a *T7 gn1* gene under the transcriptional control of the *lacUV5* promoter. The pBAD system relies on the inducible arabinose promoter that is regulated by the *araC* gene. The promoter is induced in the presence of arabinose.

The promoter and other regulatory sequences that drive expression of the  
10 antigen in the desired mammalian or vertebrate host may similarly be selected from a wide list of promoters known to be useful for that purpose. A variety of such promoters are disclosed below. In an embodiment of the immunogenic DNA plasmid composition described below, useful promoters are the human cytomegalovirus (HCMV) promoter/enhancer (described in, e.g., US Patent Nos.  
15 5,168,062 and 5,385,839, incorporated herein by reference) and the SCMV promoter enhancer.

Additional regulatory sequences for inclusion in a nucleic acid sequence, molecule or vector of this invention include, without limitation, an enhancer sequence, a polyadenylation sequence, a splice donor sequence and a splice acceptor  
20 sequence, a site for transcription initiation and termination positioned at the beginning and end, respectively, of the polypeptide to be translated, a ribosome binding site for translation in the transcribed region, an epitope tag, a nuclear localization sequence, an IRES element, a Goldberg-Hogness "TATA" element, a restriction enzyme cleavage site, a selectable marker and the like. Enhancer  
25 sequences include, e.g., the 72 bp tandem repeat of SV40 DNA or the retroviral long terminal repeats or LTRs, etc. and are employed to increase transcriptional efficiency.

These other components useful in DNA plasmids, including, e.g., origins of replication, polyadenylation sequences (e.g., BGH polyA, SV40 polyA), drug  
30 resistance markers (e.g., kanamycin resistance), and the like may also be selected from among widely known sequences, including those described in the examples and mentioned specifically below.

Selection of promoters and other common vector elements are conventional and many such sequences are available with which to design the plasmids useful in this invention. See, e.g., Sambrook *et al*, *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Laboratory, New York, (1989) and references cited therein at, for example, pages 3.18-3.26 and 16.17-16.27 and Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1989). All components of the plasmids useful in this invention may be readily selected by one of skill in the art from among known materials in the art and available from the pharmaceutical industry. Selection of plasmid components and regulatory sequences are not considered a limitation on this invention.

Examples of suitable DNA plasmid constructs for use in immunogenic compositions are described in detail in the following patent publications, which are incorporated by reference herein for such disclosures, e.g., International Patent Publication Nos. WO98/17799, WO99/43839 and WO98/17799; and United States Patent Nos. 5,593,972; 5,817,637; 5,830,876; and 5,891,505, among others.

Similarly, the selected antigen may be an antigen identified in the discussion below. In one embodiment of the immunogenic compositions herein, the selected antigen is an HIV-1 antigen, such as one expressed by *gag*, *pol*, *env*, *nef*, *vpr*, *vpu*, *vif* and *tat*. Preferably the antigen sequence and other components of the DNA plasmid are optimized, such as by codon selection appropriate to the intended host and by removal of any inhibitory sequences, also discussed below with regard to antigen preparation.

This immunogenic composition may include therefore one plasmid encoding a single selected antigen for expression in the host. According to the present method, the plasmid composition also comprises one DNA plasmid comprising a DNA sequence encoding more than one copy of the same selected antigen. Alternatively, the composition may contain one plasmid expressing multiple selected antigens. Each antigen may be under the control of separate regulatory elements or components. Alternatively, each antigen may be under the control of the same regulatory elements. In still another embodiment, the DNA plasmid composition may contain multiple plasmids, wherein each DNA plasmid encodes the same or a different antigen.

In still a further embodiment, the DNA plasmid immunogenic composition may further contain, as an individual DNA plasmid component or as part of the antigen-containing DNA plasmid, a nucleotide sequence that encodes a desirable cytokine, lymphokine or other genetic adjuvant. A host of such suitable adjuvants  
5 for which nucleic acid sequences are available are identified below. In the embodiments exemplified in this invention, a desirable cytokine for administration with the DNA plasmid composition of this invention is Interleukin-12.

The DNA plasmid composition is desirably administered in a pharmaceutically acceptable diluent, excipient or carrier, such as those discussed  
10 below. Although the composition may be administered by any selected route of administration, in one embodiment a desirable method of administration is coadministration intramuscularly of a composition comprising the plasmids with bupivacaine as the facilitating agent, described below.

In one embodiment of the method of this invention, in which the DNA  
15 composition is the priming composition, the method includes administering at least one DNA plasmid prior to the rVSV, the plasmid comprising a sequence encoding an antigen to which an immune response is desired to be induced. In another embodiment, the DNA priming composition further consists of a second plasmid encoding a selected cytokine. In still another embodiment, exemplified below, the  
20 DNA priming composition includes three plasmids, one plasmid expressing a first antigen, the second plasmid expressing the second different antigen and a third plasmid expressing a selected cytokine adjuvant. As detailed in the examples, one embodiment of a DNA priming composition contains three optimized plasmids, (1) a plasmid encoding an RNA optimized SIV *gag p37* gene (see FIG. 1A); (2) a plasmid  
25 encoding the two rhesus IL-12 subunits p35 and p40, under individual control of two promoters (see FIG. 1B) and (3) a plasmid encoding the HIV-1 gp160 env gene.

When used as a priming composition, this DNA plasmid composition is administered once or preferably, more than once prior to the boosting rVSV composition. When used as the boosting composition, this DNA plasmid  
30 composition is administered once or preferably, more than once after administration of the priming rVSV composition.

**B. rVSV Immunogenic Composition**

Another immunogenic composition useful in the methods and compositions of this invention is a replication competent, live, attenuated, vesicular stomatitis virus (VSV) delivery vehicle. This recombinant VSV comprises a nucleic acid sequence  
5 encoding the selected antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. In the methods of this invention, the antigen used in the DNA plasmid composition is the same antigen used in the rVSV immunogenic composition.

VSV is a cattle virus, which is a member of the taxonomic Order designated  
10 Mononegavirales, and comprises an 11 kb nonsegmented, negative-strand RNA genome that encodes four internal structural proteins and one exterior transmembrane protein. In 3' to 5' order, the genes encode proteins designated the nucleocapsid (N), phosphoprotein (P), matrix protein (M), transmembrane glycoprotein (G) and polymerase (L). A live VSV may be isolated and "rescued" using techniques known  
15 in the art. See, e.g., US Patent Nos. 6,044,886; 6,168,943; and 5,789,299; International Patent Publication No. WO99/02657; Conzelmann, 1998, *Ann. Rev. Genet.*, 32:123-162; Roberts and Rose, 1998, *Virol.*, 247:1-6; Lawson *et al.*, 1995 *Proc. Natl. Acad. Sci., USA* 92:4477-4481. Additionally, for example, the genomic sequence of VSV (Indiana) is set out under Accession No. NC001560 in the NCBI  
20 database. Other sequences for VSV, including VSV (Chandipura) sequences are available in that database; for example, see Accession Nos. Ay382603, Af128868, V01208, V01207, V01206, M16608, M14715, M14720 and J04350, among others. VSV strains, such as New Jersey and Indiana, among others are also available from depositories such as the American Type Culture Collection, Rockville, Maryland  
25 (see, e.g., Accession Nos. VR-1238 and VR-1239. Other sequences are described or referenced in the documents cited throughout this specification. All documents cited in this specification are incorporated herein by reference.

VSV genomes have been shown to accommodate more than one foreign gene, with expansion to at least three kilobases. The genomes of these viruses are very  
30 stable, do not undergo recombination, and rarely incur significant mutations. In addition, since their replication is cytoplasmic, and their genomes are comprised of RNA, they are incapable of integrating within the genomes of infected host cells.

Also, these negative-strand RNA viruses possess relatively simple transcriptional control sequences, which are readily manipulatable for efficient foreign gene insertion. Finally, the level of foreign gene expression can be modulated by changing the position of the foreign gene relative to the viral transcription promoter.

5 The 3' to 5' gradient of gene expression reflects the decreasing likelihood that the transcribing viral polymerase will traverse successfully each intergenic gene stop/gene start signal encountered as it progresses along the genome template. Thus, foreign genes placed in proximity to a 3' terminal transcription initiation promoter are expressed abundantly, while those inserted in more distal genomic positions, are

10 less so.

VSV replicates to high titers in a large array of different cell types, and viral proteins are expressed in great abundance. This not only means that VSV will act as a potent functional foreign gene delivery vehicle, but also, that relevant rVSV vectors can be scaled to manufacturing levels in cell lines approved for the production of

15 human biologicals.

The rVSV has a remarkable capacity to deliver foreign genes encoding critical protective immunogens from viral pathogens to a broad array of different cell types, and to subsequently cause the abundant expression of authentically-configured immunogenic proteins (Haglund, K., *et al*, 2000 *Viol.*, 268:112-21; Kahn, J. S. *et al*, 20 *1999 Virol.*, 254:81-91; Roberts, A. *et al*, 1999 *J. Virol.*, 73:3723-32; Rose, N. F. *et al*, 2000 *J. Virol.*, 74:10903-10; and Schlereth, B. *et al*. 2000 *J. Virol.*, 74:4652-7). The immunogens, so expressed, simultaneously elicit both highly durable virus neutralizing antibody responses, as well as protective cytotoxic T lymphocytes (CTL) (Roberts, A. *et al*, 1998 *J. Virol.*, 72:4704-11).

25 In addition to rVSV's efficacy, this live virus gene delivery vehicle is safe, since wild-type VSV produces little to no disease symptoms or pathology in healthy humans, even in the face of substantial virus replication (Tesh, R. B. *et al*, 1969 *Am. J. Epidemiol.*, 90:255-61). Additionally human infection with, and thus pre-existing immunity to VSV is rare. Given further attenuation, these rVSV compositions are

30 suitable for use in immunocompromised or otherwise less robust human subjects. A significant advantage of use of the VSV vector in this method is that a number of serotypes of VSV exist due to the exchange or modification of the viral attachment

protein G of the VSV. Thus, different serotypes of VSV vector carrying the same heterologous antigen can be used for repeated administration to avoid any interfering neutralizing antibody response generated to the VSV G protein by host's immune system.

5           A recombinant VSV can be designed using techniques previously described in the art, which carries the selected antigen and its regulatory sequences inserted into any position of the VSV under the control of the viral transcription promoter. In one embodiment, the heterologous gene encoding the selected antigen is inserted between the G and L coding regions of VSV. In another embodiment, the heterologous gene  
10           may be fused in the site of the G protein. In still other embodiments, the heterologous gene is fused to the site, or adjacent to, any of the other VSV genes.

          In still other embodiments, the genes are 'shuffled' to different positions in the genome. In particular, the *N* gene is 'shuffled' to different positions in the genome. Cloning to produce the shuffled recombinant cDNA sequences involves  
15           modification of the original VSV plasmid backbone (pVSV-XN1). Three variants of this original vector include plasmids that deviate from the normal gene order (3'-*N-P-M-G-L-5'*) as follows: i) 3'-*P-N-M-G-L-5'*; ii) 3'-*P-M-N-G-L-5'*; and iii) 3'-*P-M-G-N-L-5'*. The cloning strategy used to create these plasmids employs a method described by Ball, L. A. *et al.* 1999 *J. Virol.*, 73:4705-12. This technique takes  
20           advantage of the fact that the gene-end/gene-start signals found between each coding sequence are nearly identical, and allows gene rearrangements to be constructed without introducing any nucleotide substitutions. Alternatively, a few strategic point mutations may be introduced into noncoding sequences to create convenient restriction sites that facilitate genome rearrangements.

25           In still further embodiments of these vectors, the carboxy-terminal coding sequence for the 29 amino acid cytoplasmic domain of the *G* gene is truncated by deleting amino acids from the 5' C terminus of the *G* gene. Alternatively, the *G* gene is deleted entirely. In one embodiment, the entire cytoplasmic domain of the *G* gene is removed. In another embodiment at least 28 amino acids of the cytoplasmic  
30           domain are removed. In still a further embodiment, about 20 amino acids of the cytoplasmic domain are deleted. In still a further embodiment, about 10 or fewer amino acids of the cytoplasmic domain are deleted.

Both the shuffled genome approach and the G protein modification approach reportedly generate partial growth defects (Flanagan, E. B., *et al* 2001 *J. Virol.* 75:6107-14; Schnell, M. J. *et al.* 1998 *EMBO J.*, 17:1289-96). It is anticipated that such modifications of the VSV may lead to a more attenuated phenotype or even to a non-replicating VSV for use in various embodiments of the present invention. See, e.g., Johnson, J. E. *et al*, 1998 *Virol.*, 251:244-52.37; Johnson, J. E., *et al.*, 1997 *J. Virol.*, 71:5060-8.

Similarly, the selected antigen may be an antigen identified in the discussion below. In one embodiment of the immunogenic compositions herein, the selected antigen is an HIV-1 *gag* and/or *env* (*gp160*) gene of clade B virus isolate. In still other embodiments, the antigen is an HIV-1 *pol*, *nef*, *vpr*, *vpu*, *vif* or *tat* gene. Preferably the antigen sequence is optimized, such as by codon selection appropriate to the intended host and/or by removal of any inhibitory sequences, also discussed below with regard to antigen preparation.

To overcome any potential problem of diminished vector replication efficiencies with sequential administration, a vector set of similar design, each carrying a *G* gene from a different VSV serotype, permits successful booster immunizations. The primary amino acid sequences of the G proteins from VSV Indiana, New Jersey, and Chandipura, are sufficiently divergent such that preexisting immunity to one does not preclude infection and replication of the others. Thus, the neutralizing antibody response generated by rVSV (Indiana) should not interfere with replication of either rVSV (New Jersey) or rVSV (Chandipura). A vector set that can permit successful sequential immunizations can be prepared by replacing the *G* gene from VSV Indiana with either the divergent homolog from VSV Chandipura or from VSV New Jersey, forming three immunologically distinct vectors.

This rVSV immunogenic composition may include therefore one rVSV encoding a single selected antigen for expression in the host. According to the present method, the rVSV immunogenic composition comprises one rVSV comprising a nucleic acid sequence encoding more than one copy of the same selected antigen. Alternatively, the composition may contain one rVSV expressing multiple selected antigens. Each antigen may be under the control of separate regulatory elements or components. Alternatively, each antigen may be under the

control of the same regulatory elements. In still another embodiment, the rVSV composition may contain multiple rVSVs, wherein each rVSV encodes the same or a different antigen.

5 In still a further embodiment, the rVSV immunogenic composition may further contain or be administered with, a cytokine, lymphokine or genetic adjuvant. The cytokine may be administered as a protein or in a plasmid as above-mentioned or be encoded by insertion of the cytokine encoding sequence in a recombinant VSV. For example, the cytokine encoding sequence may be inserted into any position in the VSV genome and expressed from the viral transcription promoter. A host of such  
10 suitable adjuvants for which nucleic acid sequences are available are identified below. In the embodiments exemplified in this invention, a desirable cytokine for administration with the rVSV composition of this invention is Interleukin-12.

The rVSV composition is desirably administered in a pharmaceutically acceptable diluent, excipient or carrier, such as those discussed below. Although the  
15 composition may be administered by any selected route of administration, in one embodiment a desirable method of administration is intranasal.

In one embodiment of the method of this invention, in which the rVSV composition is the boosting composition, the method includes administering at least one rVSV immunogenic composition after administration of a DNA immunogenic  
20 priming composition. The rVSV composition expresses the same antigen as expressed by the priming composition. In one embodiment, the rVSV composition includes an additional recombinant virus encoding a selected cytokine. In still another embodiment, the rVSV includes a sequence expressing a cytokine, e.g., IL-12 present in the same rVSV as is expressing the antigen. In still another  
25 embodiment, multiple rVSV compositions are administered as later boosters. In one embodiment at least two rVSV compositions are administered following the priming compositions. In another embodiment at least three rVSV compositions are administered following the priming compositions.

Desirably, as discussed above, each subsequent rVSV composition has a  
30 different serotype, but the same antigen encoding sequence. The different serotypes are selected from among known naturally occurring serotypes and from among any synthetic serotypes provided by manipulation of the VSV G protein. Among known



methods for altering the G protein of rVSV are the technology described in International Publication No. WO99/32648 and Rose, N. F. *et al.* 2000 *J. Virol.*, 74:10903-10.

In another embodiment, each rVSV has a different antigen encoding sequence, but the same VSV G protein. In still another embodiment, each rVSV has a different antigen encoding sequence, and a different VSV G protein. As detailed in the examples, one embodiment of a series of rVSV boosting compositions comprises two optimized rVSVs containing an HIV-1 *gp160 env* gene, with one rVSV being the Indiana serotype and the other being the Chandipura serotype.

According to the present invention, this rVSV immunogenic composition may be administered as a boosting composition subsequent to the administration of the priming DNA immunogenic composition that presents the same antigen to the host. In any of the embodiments of the method of the invention, the second and any additional rVSV is administered as a booster following the first rVSV administration.

The additional rVSV boosters in one embodiment are of the same serotype bearing the same antigen. Alternatively, the additional rVSV boosters having different serotypes are serially administered before administration of the boosting DNA immunogenic composition. It has been shown to be useful to administer at least three boosters. When used as a boosting composition, the rVSV compositions are administered serially, after the priming DNA immunogenic compositions. When used as the priming composition, the rVSV immunogenic composition is administered once or preferably multiple times. The additional rVSV boosters in one embodiment are of the same serotype bearing the same antigen. Alternatively, the additional rVSV boosters having different serotypes are serially administered before administration of the boosting DNA immunogenic composition.

Examples of suitable rVSV constructs that are capable of expressing an HIV-1 protein *in vivo* are described in detail in the following examples, and in the following publications, e.g., Rose *et al.*, 2000 *Virol.*, 268:112-121; Rose *et al.*, 2000 *J. Virol.*, 74:10903-10910; Rose *et al.* 2001 *Cell*, 106:539-549; Rose *et al.*, 2002 *J. Virol.*, 76:2730-2738; Rose *et al.*, 2002 *J. Virol.*, 76:7506-7517, which are incorporated herein by reference. Additional rVSV vectors may be further attenuated, either by progressive truncations of the VSV G protein, or by VSV

structural gene shuffling as mentioned above. Non-replicating VSV may also be used according to this invention. rVSVs displaying a desired balance of attenuation and immunogenicity are anticipated to be useful in this invention.

Several illustrative rVSV constructs exemplified in the Examples below have the recombinant genomes:

- (1) 3' N- P- M- G-HIV *env*-L-5'
- (2) 3' N- P- M- G-HIV *gag*-L-5'
- (3) 3' N- P- M- G-SIV *gag*-L-5'.

In one embodiment, a method and immunogenic composition of this invention employs one of these rVSV constructs. In another embodiment, a method and immunogenic composition of this invention employ both an rVSV-HIV *env* and an rVSV-HIV *gag*. This latter immunogenic composition simultaneously elicits potent humoral immune responses to authentically configured gp160, plus CTL (to Env and Gag) capable of killing HIV-1 virus infected cells. The HIV-1 gp160 expressed in this manner binds to CD4/co-receptor and undergoes the conformational changes associated with receptor binding. Proper gp160/ receptor interactions expose the cryptic virus neutralizing determinants present on gp160 which are required for the induction of antibody-mediated protection from infection (see, e.g., LaCasse, R. A. *et al*, 1999 *Science*. 283:357-62).

### C. *Antigens for Use in the Immunogenic Compositions of this Invention*

The antigenic or immunogenic compositions useful in the methods and compositions of this invention enhance the immune response in a vertebrate host to a selected antigen. The selected antigen, when expressed by the plasmid DNA or VSV, may be a protein, polypeptide, peptide, fragment or a fusion thereof derived from a pathogenic virus, bacterium, fungus or parasite. Alternatively, the selected antigen may be a protein, polypeptide, peptide, fragment or fusion thereof derived from a cancer cell or tumor cell. In another embodiment, the selected antigen may be a protein, polypeptide, peptide, fragment or fusion thereof derived from an allergen so as to interfere with the production of IgE so as to moderate allergic responses to the allergen. In still another embodiment, the selected antigen may be a protein, polypeptide, peptide, fragment or fusion thereof derived from a molecule or portion

thereof which represents those produced by a host (a self molecule) in an undesired manner, amount or location, such as those from amyloid precursor protein, so as to prevent or treat disease characterized by amyloid deposition in a vertebrate host. In one embodiment of this invention, the selected antigen is a protein, polypeptide, peptide or fragment derived from HIV-1.

The invention is also directed to methods for increasing the ability of an immunogenic composition containing a selected antigen (1) from a pathogenic virus, bacterium, fungus or parasite to elicit the immune response of a vertebrate host, or (2) from a cancer antigen or tumor-associated antigen from a cancer cell or tumor cell to elicit a therapeutic or prophylactic anti-cancer effect in a vertebrate host, or (3) from an allergen so as to interfere with the production of IgE so as to moderate allergic responses to the allergen, or (4) from a molecule or portion thereof which represents those produced by a host (a self molecule) in an undesired manner, amount or location, so as to reduce such an undesired effect.

In another embodiment, desirable viral immunogenic compositions utilizing the prime/boost regimen of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, Human immunodeficiency virus, Simian immunodeficiency virus, Respiratory syncytial virus, Parainfluenza virus types 1-3, Influenza virus, Herpes simplex virus, Human cytomegalovirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human papillomavirus, Poliovirus, rotavirus, caliciviruses, Measles virus, Mumps virus, Rubella virus, adenovirus, rabies virus, canine distemper virus, rinderpest virus, Human metapneumovirus, avian pneumovirus (formerly turkey rhinotracheitis virus), Hendra virus, Nipah virus, coronavirus, parvovirus, infectious rhinotracheitis viruses, feline leukemia virus, feline infectious peritonitis virus, avian infectious bursal disease virus, Newcastle disease virus, Marek's disease virus, porcine respiratory and reproductive syndrome virus, equine arteritis virus and various Encephalitis viruses.

In another embodiment, desirable bacterial immunogenic compositions utilizing the prime/boost regimen of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, *Haemophilus influenzae* (both typable and nontypable), *Haemophilus somnus*, *Moraxella catarrhalis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus*

*agalactiae, Streptococcus faecalis, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae, Chlamydia trachomatis, Chlamydia pneumoniae, Chlamydia psittaci, Bordetella pertussis, Alloiococcus otiditis, Salmonella typhi, Salmonella typhimurium, Salmonella choleraesuis, Escherichia coli, Shigella, Vibrio cholerae, Corynebacterium diphtheriae, Mycobacterium tuberculosis, Mycobacterium avium-Myco*  
 5 *bacterium intracellulare complex, Proteus mirabilis, Proteus vulgaris, Staphylococcus aureus, Staphylococcus epidermidis, Clostridium tetani, Leptospira interrogans, Borrelia burgdorferi, Pasteurella haemolytica, Pasteurella multocida, Actinobacillus pleuropneumoniae and Mycoplasma gallisepticum.*

10 In another embodiment, desirable immunogenic compositions against fungal pathogens utilizing the prime/boost regimen of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, *Aspergillus, Blastomyces, Candida, Coccidioides, Cryptococcus and Histoplasma.*

In another embodiment, desirable immunogenic compositions against  
 15 parasites utilizing the prime/boost regimen of this invention include those directed to the prevention and/or treatment of disease caused by, without limitation, *Leishmania major, Ascaris, Trichuris, Giardia, Schistosoma, Cryptosporidium, Trichomonas, Toxoplasma gondii and Pneumocystis carinii.*

In another embodiment, desirable immunogenic compositions for eliciting a  
 20 therapeutic or prophylactic anti-cancer effect in a vertebrate host, which utilize the prime/boost regimen of this invention include those utilizing a cancer antigen or tumor-associated antigen, including, without limitation, prostate specific antigen, carcino-embryonic antigen, MUC-1, Her2, CA-125 and MAGE-3.

Nucleotide and protein sequences for the above-listed, known antigens are  
 25 readily publicly available through databases such as NCBI, or may be available from other sources such as the American Type Culture Collection and universities.

Desirable immunogenic compositions for moderating responses to allergens  
 in a vertebrate host, which utilize the prime/boost regimen of this invention include  
 those containing an allergen or fragment thereof. Examples of such allergens are  
 30 described in United States Patent No. 5,830,877 and International Patent Publication No. WO99/51259, which are hereby incorporated by reference. Such allergens include, without limitation, pollen, insect venoms, animal dander, fungal spores and

drugs (such as penicillin). These immunogenic compositions interfere with the production of IGE antibodies, a known cause of allergic reactions.

Desirable immunogenic compositions for moderating responses to self molecules in a vertebrate host, which utilize the prime/boost regimen of this invention, include those containing a self molecule or fragment thereof. Examples of such self molecules include the  $\beta$ -chain insulin involved in diabetes, the G17 molecule involved in gastroesophageal reflux disease, and antigens which down regulate autoimmune responses in diseases such as multiple sclerosis, lupus and rheumatoid arthritis. Also included is the  $\beta$ -amyloid peptide (also referred to as A $\beta$  peptide), which is an internal, 39-43 amino acid fragment of amyloid precursor protein (APP), which is generated by processing of APP by the  $\beta$  and  $\gamma$  secretase enzymes. The A $\beta$ 1-42 peptide has the following sequence SEQ ID NO: 1:  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe  
Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val  
Val Ile Ala.

It is also desirable in selection and use of the antigenic sequences for design of the DNA plasmids and rVSV constructs of this invention to alter codon usage of the selected antigen-encoding gene sequence, as well as the DNA plasmids into which they are inserted, and/or to remove inhibitory sequences therein. The removal of inhibitory sequences can be accomplished by using the technology discussed in detail in US Patent Nos. 5,965,726; 5,972,596; 6,174,666; 6,291,664; and 6,414,132; and in International Patent Publication No. WO01/46408, incorporated by reference herein. Briefly described, this technology involves mutating identified inhibitor/instability sequences in the selected gene, preferably with multiple point mutations.

As one specific embodiment exemplified below, the immunogenic plasmid and rVSV compositions of this invention desirably employ one or more sequences optimized to encode HIV-1 antigens, such as the gag, pol and nef antigens, or immunogenic fragments or fusions thereof. The *gag* and *env* genes of the chimeric simian-human immunodeficiency virus (SHIV) (89.6P) are useful to make rVSVs, such that protection from infection and mitigation of virus burden and disease can be

demonstrated in a Rhesus macaque model of disease. The examples below demonstrate use of the SHIV analogs, i.e. SIV *gag* and HIV 89.6P *env*.

**D. Promoters Useful in the Immunogenic DNA Plasmid or rVSV Constructs**

5           Suitable promoters for use in any of the components of this invention may be readily selected from among constitutive promoters, inducible promoters, tissue-specific promoters and others. Examples of constitutive promoters that are non-specific in activity and employed in the nucleic acid molecules encoding an antigen of this invention include, without limitation, the retroviral Rous sarcoma virus (RSV) promoter, the retroviral LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) (see, e.g., Boshart *et al*, 1985 *Cell*, 41:521-530), the SV40 promoter, the dihydrofolate reductase promoter, the  $\beta$ -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 $\alpha$  promoter (Invitrogen). Inducible promoters that are regulated by exogenously supplied compounds, include, without limitation, the arabinose promoter, the zinc-inducible sheep metallothioneine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088); the ecdysone insect promoter (No *et al*, 1996 *Proc. Natl. Acad. Sci. USA*, 93:3346-3351), the tetracycline-repressible system (Gossen *et al*, 1992 *Proc. Natl. Acad. Sci. USA*, 89:5547-5551), the tetracycline-inducible system (Gossen *et al*, 1995 *Science*, 268:1766-1769, see also Harvey *et al*, 1998 *Curr. Opin. Chem. Biol.*, 2:512-518), the RU486-inducible system (Wang *et al*, 1997 *Nat. Biotech.*, 15:239-243 and Wang *et al*, 1997 *Gene Ther.*, 4:432-441) and the rapamycin-inducible system (Magari *et al*, 1997 *J. Clin. Invest.*, 100: 2865-2872).

Other types of inducible promoters that may be useful in this context are those regulated by a specific physiological state, e.g., temperature or acute phase or in replicating cells only. Useful tissue-specific promoters include the promoters from genes encoding skeletal  $\beta$ -actin, myosin light chain 2A, dystrophin, muscle creatine kinase, as well as synthetic muscle promoters with activities higher than naturally-occurring promoters (see Li *et al.*, 1999 *Nat. Biotech.*, 17:241-245). Examples of promoters that are tissue-specific are known for the liver (albumin, Miyatake *et al*.

1997 *J. Virol.*, 71:5124-32; hepatitis B virus core promoter, Sandig *et al.*, 1996 *Gene Ther.*, 3: 1002-9; alpha-fetoprotein (AFP), Arbuthnot *et al.*, 1996 *Hum. Gene Ther.*, 7:1503-14), bone (osteocalcin, Stein *et al.*, 1997 *Mol. Biol. Rep.*, 24:185-96; bone sialoprotein, Chen *et al.*, 1996 *J. Bone Miner. Res.*, 11:654-64), lymphocytes (CD2, Hansal *et al.*, 1988 *J. Immunol.*, 161:1063-8; immunoglobulin heavy chain; T cell receptor  $\alpha$  chain), neuronal (neuron-specific enolase (NSE) promoter, Andersen *et al.*, 1993 *Cell. Mol. Neurobiol.*, 13:503-15; neurofilament light-chain gene, Piccioli *et al.*, 1991 *Proc. Natl. Acad. Sci. USA*, 88:5611-5; the neuron-specific *ngf* gene, Piccioli *et al.*, 1995 *Neuron*, 15:373-84); among others. See, e.g., International Patent Publication No. WO00/55335 for additional lists of known promoters useful in this context.

#### ***E. Carriers, Excipients, Adjuvants and Formulations Useful for the Immunogenic Compositions of this Invention***

15 The immunogenic compositions useful in this invention, whether the DNA plasmid or rVSV compositions, further comprise an immunologically acceptable diluent or a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. The antigenic compositions may also be mixed with such diluents or carriers in a conventional manner. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with administration to humans or other vertebrate hosts. The appropriate carrier is evident to those skilled in the art and will depend in large part upon the route of administration.

25 Still additional components that may be present in the immunogenic compositions of this invention are adjuvants, preservatives, surface active agents, and chemical stabilizers, suspending or dispersing agents. Typically, stabilizers, adjuvants, and preservatives are optimized to determine the best formulation for efficacy in the target human or animal.

#### ***1. Adjuvants***

30 An adjuvant is a substance that enhances the immune response when administered together with an immunogen or antigen. A number of cytokines or

lymphokines have been shown to have immune modulating activity, and thus may be used as adjuvants, including, but not limited to, the interleukins 1- $\alpha$ , 1- $\beta$ , 2, 4, 5, 6, 7, 8, 10, 12 (see, e.g., U.S. Patent No. 5,723,127), 13, 14, 15, 16, 17 and 18 (and its mutant forms), the interferons- $\alpha$ ,  $\beta$  and  $\gamma$ , granulocyte-macrophage colony stimulating factor (see, e.g., U.S. Patent No. 5,078,996 and ATCC Accession Number 39900), macrophage colony stimulating factor, granulocyte colony stimulating factor, GSF, and the tumor necrosis factors  $\alpha$  and  $\beta$ . Still other adjuvants useful in this invention include a chemokine, including without limitation, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES. Adhesion molecules, such as a selectin, e.g., L-selectin, P-selectin and E-selectin may also be useful as adjuvants. Still other useful adjuvants include, without limitation, a mucin-like molecule, e.g., CD34, GlyCAM-1 and MadCAM-1, a member of the integrin family such as LFA-1, VLA-1, Mac-1 and p150.95, a member of the immunoglobulin superfamily such as PECAM, ICAMs, e.g., ICAM-1, ICAM-2 and ICAM-3, CD2 and LFA-3, co-stimulatory molecules such as CD40 and CD40L, growth factors including vascular growth factor, nerve growth factor, fibroblast growth factor, epidermal growth factor, B7.2, PDGF, BL-1, and vascular endothelial growth factor, receptor molecules including Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, and DR6. Still another adjuvant molecule includes Caspase (ICE). See, also International Patent Publication Nos. WO98/17799 and WO99/43839, incorporated herein by reference.

Suitable adjuvants used to enhance an immune response include, without limitation, MPL<sup>TM</sup> (3-O-deacylated monophosphoryl lipid A; Corixa, Hamilton, MT), which is described in U.S. Patent No. 4,912,094, which is hereby incorporated by reference. Also suitable for use as adjuvants are synthetic lipid A analogs or aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are available from Corixa (Hamilton, MT), and which are described in United States Patent No. 6,113,918, which is hereby incorporated by reference. One such AGP is 2-[(R)-3-Tetradecanoyloxytetradecanoylamino] ethyl 2-Deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyoxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoyl-amino]- $\beta$ -D-glucopyranoside, which is also known as



529 (formerly known as RC529). This 529 adjuvant is formulated as an aqueous form or as a stable emulsion.

Still other adjuvants include mineral oil and water emulsions, aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, etc.,  
5 Amphigen, Avridine, L121/squalene, D-lactide-poly(lactide)/glycoside, pluronic polyols, muramyl dipeptide, killed *Bordetella*, saponins, such as Stimulon™ QS-21 (Antigenics, Framingham, MA.), described in U.S. Patent No. 5,057,540, which is hereby incorporated by reference, and particles generated therefrom such as ISCOMS (immunostimulating complexes), *Mycobacterium tuberculosis*, bacterial  
10 lipopolysaccharides, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Patent No. 6,207,646, which is hereby incorporated by reference), a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT), particularly LT-K63, LT-R72, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, incorporated herein by reference.

15 Also useful as adjuvants are cholera toxins and mutants thereof, including those described in published International Patent Application number WO 00/18434 (wherein the glutamic acid at amino acid position 29 is replaced by another amino acid (other than aspartic acid), preferably a histidine). Similar CT toxins or mutants are described in  
20 published International Patent Application number WO 02/098368 (wherein the isoleucine at amino acid position 16 is replaced by another amino acid, either alone or in combination with the replacement of the serine at amino acid position 68 by another amino acid; and/or wherein the valine at amino acid position 72 is replaced by another amino acid). Other CT toxins are described in published  
25 International Patent Application number WO 02/098369 (wherein the arginine at amino acid position 25 is replaced by another amino acid; and/or an amino acid is inserted at amino acid position 49; and/or two amino acids are inserted at amino acid positions 35 and 36).

In one embodiment exemplified below, the desired adjuvant is IL-12,  
30 which is expressed from a plasmid. See, e.g., US Patent Nos. 5,457,038; 5,648,467; 5,723,127 and 6,168,923, incorporated by reference herein. This IL-12 expressing

plasmid is incorporated into the immunogenic DNA plasmid-containing priming composition of the examples. However, it should be noted that this plasmid could be administered to the mammalian or vertebrate host with the rVSV composition (or expressed by the rVSV) or alone, between the priming and boosting compositions.

5 In one embodiment, the cytokine may be administered as a protein. In a preferred embodiment, the cytokine is administered as a nucleic acid composition comprising a DNA sequence encoding the cytokine under the control of regulatory sequences directing expression thereof in a mammalian cell. In still another useful  
10 embodiment, the cytokine-expressing plasmid is administered with the DNA composition. In still another embodiment, the cytokine is administered between the administrations of the priming composition and the boosting composition. In yet another step, the cytokine is administered with the boosting step. In still another embodiment, the cytokine is administered with both priming and boosting compositions.

15 Where the priming composition is the DNA plasmid composition, as in the examples below, the plasmid composition can comprise a DNA sequence encoding the cytokine under the control of regulatory sequences directing expression thereof in the mammalian cell. In some embodiments, the cytokine-encoding sequence is present on the same DNA plasmid as the antigen-encoding sequence. In  
20 still other embodiments, the cytokine-encoding sequence is present on a DNA plasmid different from the DNA plasmid encoding the antigen.

## 2. *Facilitating Agents or Co-Agents*

In addition to a carrier as described above, immunogenic compositions composed of polynucleotide molecules desirably contain optional  
25 polynucleotide facilitating agents or "co-agents", such as a local anesthetic, a peptide, a lipid including cationic lipids, a liposome or lipidic particle, a polycation such as polylysine, a branched, three-dimensional polycation such as a dendrimer, a carbohydrate, a cationic amphiphile, a detergent, a benzylammonium surfactant, or another compound that facilitates polynucleotide transfer to cells. Such a facilitating  
30 agent includes the local anesthetic bupivacaine or tetracaine (*see* U.S. Patent Nos. 5,593,972; 5,817,637; 5,380,876; 5,981,505 and 6,383,512 and International Patent Publication No. WO98/17799, which are hereby incorporated by reference). Other

non-exclusive examples of such facilitating agents or co-agents useful in this invention are described in U. S. Patent Nos. 5,703,055; 5,739,118; 5,837,533; International Patent Publication No. WO96/10038, published April 4, 1996; and International Patent Publication No WO94/16737, published August 8, 1994, which  
5 are each incorporated herein by reference.

Most preferably, the local anesthetic is present in an amount that forms one or more complexes with the nucleic acid molecules. When the local anesthetic is mixed with nucleic acid molecules or plasmids of this invention, it forms a variety of small complexes or particles that pack the DNA and are  
10 homogeneous. Thus, in one embodiment of the immunogenic compositions of this invention, the complexes are formed by mixing the local anesthetic and at least one plasmid of this invention. Any single complex resulting from this mixture may contain a variety of combinations of the different plasmids. Alternatively, in another embodiment of the compositions of this invention, the local anesthetic may be pre-  
15 mixed with each plasmid separately. The separate mixtures are then combined in a single composition to ensure the desired ratio of the plasmids is present in a single immunogenic composition, if all plasmids are to be administered in a single bolus administration. Alternatively, the local anesthetic and each plasmid may be mixed separately and administered separately to obtain the desired ratio.

Where, hereafter, the term "complex" or "one or more complexes" or "complexes" is used to define this embodiment of the immunogenic composition, it is understood that the term encompasses one or more complexes. Each complex contains a mixture of the plasmids, or a mixture of complexes formed discretely. Each complex can contain only one type of plasmid or complex, or a mixture of  
25 plasmids or complexes, wherein each complex contains a polycistronic DNA. Preferably, the complexes are between about 50 to about 150 nm in diameter. When the facilitating agent used is a local anesthetic, preferably bupivacaine, an amount from about 0.1 weight percent to about 1.0 weight percent based on the total weight of the polynucleotide composition is preferred. See, also, International Patent  
30 Publication No. WO99/21591, which is hereby incorporated by reference, and which teaches the incorporation of benzylammonium surfactants as co-agents, preferably administered in an amount between about 0.001-0.03 weight %. According to the

present invention, the amount of local anesthetic is present in a ratio to said nucleic acid molecules of 0.01-2.5% w/v local anesthetic to 1-10  $\mu\text{g/ml}$  nucleic acid. Another such range is 0.05-1.25% w/v local anesthetic to 100  $\mu\text{g/ml}$  to 1 mg/ml nucleic acid.

5                    3.    ***Other Additives to the Immunogenic Compositions***

Other additives can be included in the immunogenic compositions of this invention, including preservatives, stabilizing ingredients, surface active agents, and the like.

10                    Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.

Suitable stabilizing ingredients that may be used include, for example, casamino acids, sucrose, gelatin, phenol red, N-Z amine, monopotassium diphosphate, lactose, lactalbumin hydrolysate, and dried milk.

15                    Suitable surface active substances include, without limitation, Freund's incomplete adjuvant, quinone analogs, hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin, dimethyl-dioctadecylammonium bromide), methoxyhexadecylglycerol, and pluronic polyols; polyamines, e.g., pyran, dextran sulfate, poly IC, carbopol; peptides, e.g., muramyl peptide and dipeptide, 20                    dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum phosphate, etc. and immune stimulating complexes (ISCOMS). The plasmids and rVSVs may also be incorporated into liposomes for use as an immunogenic composition. The immunogenic compositions may also contain other additives suitable for the selected mode of administration of the composition. The composition of the invention may 25                    also involve lyophilized polynucleotides, which can be used with other pharmaceutically acceptable excipients for developing powder, liquid or suspension dosage forms. See, e.g., Remington: The Science and Practice of Pharmacy, Vol. 2, 19<sup>th</sup> edition (1995), e.g., Chapter 95 Aerosols; and International Patent Publication No. WO99/45966, the teachings of which are hereby incorporated by reference.

30                    These immunogenic compositions can contain additives suitable for administration via any conventional route of administration. In some preferred embodiments, the immunogenic composition of the invention is prepared for

administration to human subjects in the form of, for example, liquids, powders, aerosols, tablets, capsules, enteric-coated tablets or capsules, or suppositories. Thus, the immunogenic compositions may also include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. In one embodiment of a formulation for parenteral administration, the active ingredient is provided in dry (*i.e.*, powder or granular) form for reconstitution with a suitable vehicle (*e.g.*, sterile pyrogen-free water) prior to parenteral administration of the reconstituted composition. Other useful parenterally-administrable formulations include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer system. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.

The immunogenic compositions of the present invention, are not limited by the selection of the conventional, physiologically acceptable, carriers, adjuvants, or other ingredients useful in pharmaceutical preparations of the types described above. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional characteristics is within the skill of the art.

***F. Dosages and Routes of Administration for Immunogenic Compositions of the Present Invention***

In general, selection of the appropriate "effective amount" or dosage for the components of the immunogenic composition(s) of the present invention will also be based upon the identity of the antigen in the immunogenic composition(s) employed, as well as the physical condition of the subject, most especially including the general health, age and weight of the immunized subject. The method and routes of administration and the presence of additional components in the immunogenic compositions may also affect the dosages and amounts of the plasmid and rVSV compositions. Such selection and upward or downward adjustment of the effective dose is within the skill of the art. The amount of plasmid and rVSV required to induce an immune response, preferably a protective response, or produce an

exogenous effect in the patient without significant adverse side effects varies depending upon these factors. Suitable doses are readily determined by persons skilled in the art.

The antigenic or immunogenic compositions of this invention are  
5 administered to a human or to a non-human vertebrate by a variety of routes including, but not limited to, intranasal, oral, vaginal, rectal, parenteral, intradermal, transdermal (*see, e.g.,* International patent publication No. WO 98/20734, which is hereby incorporated by reference), intramuscular, intraperitoneal, subcutaneous, intravenous and intraarterial. The appropriate route is selected depending on the  
10 nature of the immunogenic composition used, and an evaluation of the age, weight, sex and general health of the patient and the antigens present in the immunogenic composition, and similar factors by an attending physician.

In the examples provided below, the immunogenic DNA compositions are administered intramuscularly (i.m.). In one embodiment, it is desirable to administer  
15 the rVSV compositions intranasally, rather than im. However, the selection of dosages and routes of administration are not limitations upon this invention.

Similarly, the order of immunogenic composition administration and the time periods between individual administrations may be selected by the attending physician or one of skill in the art based upon the physical characteristics and precise  
20 responses of the host to the application of the method. Such optimization is expected to be well within the skill of the art.

#### ***G. Kit Components***

In still another embodiment, the present invention provides a pharmaceutical kit for ready administration of an immunogenic, prophylactic, or therapeutic regimen  
25 for treatment of any of the above-noted diseases or conditions for which an immune response to an antigen is desired. This kit is designed for use in a method of inducing a high level of antigen-specific immune response in a mammalian or vertebrate subject. The kit contains at least one immunogenic composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under  
30 the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. Preferably multiple prepackaged dosages of the DNA immunogenic composition are provided in the kit for multiple administrations. The kit also

contains at least one immunogenic composition comprising a replication competent, recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the same antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. Preferably multiple  
5 prepackaged dosages of the rVSV immunogenic composition are provided in the kit for multiple administrations.

Where the above-described immunogenic compositions do not also contain DNA plasmids and/or rVSV that express a cytokine, such as IL-12, the kit also optionally contains a separate cytokine composition or multiple prepackaged dosages  
10 of the cytokine composition for multiple administrations. These cytokine compositions are generally nucleic acid compositions comprising a DNA sequence encoding the selected cytokine under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell.

The kit also contains instructions for using the immunogenic compositions in  
15 a prime/boost method as described herein. The kits may also include instructions for performing certain assays, various carriers, excipients, diluents, adjuvants and the like above-described, as well as apparatus for administration of the compositions, such as syringes, spray devices, etc. Other components may include disposable gloves, decontamination instructions, applicator sticks or containers, among other  
20 compositions.

In order that this invention may be better understood, the following examples are set forth. The examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention. All documents, publications and patents cited in the following examples are incorporated by  
25 reference herein.

As demonstrated in the Examples below, a prime/boost protocol of this invention induces in the immunized subject a surprising synergistic effect on antigen-specific cellular and humoral immune responses. In fact, when these responses induced by a prime/boost protocol of this invention are compared to the results of  
30 administering multiple priming compositions only or multiple boosting compositions only, the synergistic nature of the response to the compositions of this invention is dramatically evident. The combination of the presentation of the desired antigen by a

DNA plasmid administration followed by a rVSV boost produces an increase in antigen-specific T cells in the immunized subject, that is considerably in excess of any additive response. Similarly, the increase demonstrated in the humoral response to the desired antigen is unexpectedly high with the use of both the DNA plasmid and rVSV immunogenic compositions in an immunization protocol. See, for example, Table 1 below and FIGS. 4 and 5.

#### EXAMPLE 1: PREPARATION OF DNA PLASMIDS

This example describes illustrative plasmids useful in one embodiment of this invention as set out in Examples 2 and 3. These plasmids are not a limitation on the present invention, but have been optimized for use in the subsequent experiments. The following DNA immunogenic compositions were designed utilizing standard recombinant DNA techniques. The DNA backbone vector expressing HIV or SIV *gag* genes utilizes the HCMV promoter, BGH poly A termination sequence, the ColE1 bacterial origin of replication (ori); and a kanamycin resistance gene for selection.

##### A. *SIV gag p37 DNA Plasmid*

Plasmid WLV102 is a bacterial plasmid expressing as the selected antigen against which an immune response was desired, the SIV *gag* p37. Plasmid WLV102 (4383bp) consists of an RNA optimized truncated *gag* gene (p37) from SIV (Qiu *et al*, 1999 *J. Virol.*, 73:9145-9152) inserted into the DNA plasmid expression vector WLV001. The *gag* gene was RNA optimized by inactivating the inhibitory sequences, thus allowing high level Rev independent expression of *gag* gene, using the technology discussed in detail in US Patent Nos. 5,965,726; 5,972,596; 6,174,666; 6,291,664; and 6,414,132; and in International Patent Publication No. WO01/46408, incorporated by reference herein.

The WLV102 plasmid backbone consists of three genetic units. The first is a eukaryotic gene expression unit that contains genetic elements from the HCMV immediate early promoter/enhancer (Boshart *et al.* 1985, cited above) and the BGH polyadenylation signal (Goodwin EC and Rottman FM, 1982 *J. Biol. Chem.* 267: 16330-16334). The *gag* gene is cloned between Sall and EcoRI sites. The second component is a chimeric kanamycin resistance gene (*kan'*) gene, adenyl 4'-



nucleotidyl transferase type Ia (see United States Patent No. 5,851,804). This gene has been devised to confer resistance to limited number of aminoglycosides while it enables selection of bacteria containing the plasmid. The third component is a ColE1 bacterial origin of replication that is required for the propagation of the plasmid during fermentation of bacteria. This plasmid is illustrated in FIG. 1A.

**B. Plasmids Encoding a Cytokine – rIL-12 DNA**

The Rhesus IL-12 WLV104 plasmid is a dual promoter construct expressing the heterodimeric form of rhesus IL-12. Plasmid WLV103 is a dual promoter expression plasmid consisting of two genes encoding human IL12 proteins p35 and p40. The plasmid has a total of 6259 nucleotides. Each cistron in WLV103 containing one of the two interleukin 12 subunits, p35 or p40, is under the control of separate regulatory elements. The p35 subunit is under the control of HCMV promoter/enhancer, and the SV40 polyadenylation signal (cloned between SalI and MluI sites). The p40 subunit is under the control of the SCMV promoter and has a BGH polyadenylation signal (cloned into XhoI site).

The plasmid backbone consists of several components. The first is a eukaryotic gene expression unit that contains genetic elements from the HCMV immediate early promoter/enhancer and SV 40 polyadenylation signal (Fitzgerald M and Shenk T., 1981 *Cell*, 24: 251-260). The second component is a eukaryotic gene expression unit, composed of the SCMV promoter (Jeang *et al.* 1987 *J. Virol.*, 61: 1559-1570) and the BGH polyadenylation signal. The third component is a chimeric kanamycin resistance gene (*km'*) gene, adeny 4'- nucleotidyl transferase type Ia. The fourth component is a ColE1 bacterial origin of replication that is required for the propagation of the plasmid in bacteria.

The resulting plasmid vectors SIV gag/HIV gag and IL-12 DNA were analyzed by restriction enzyme digest. The plasmids were transiently transfected in Rhabdosarcoma cells grown in DMEM+10% fetal calf serum (FCS) medium and antibiotics. These cells were then analyzed for appropriate expression of the viral proteins using a specific monoclonal antibody for HIV gag (ABI) and polyclonal serum from rhesus (from SIV infected animals) for SIV gag in a Western Blot assay. IL-12 was detected in the supernatant with ELISA kits (R&D Systems) that detect p70 protein.

The plasmid vectors were expanded in transformed DH10B cells grown in LB medium supplemented with kanamycin, and were purified using the Qiagen kit according to manufacturer's specifications. The DNA was then analyzed by electrophoresis on an agarose gel against a known standard.

- 5 For use in the following experiments each plasmid was formulated at a concentration of 2.5 mg/mL in 0.25% bupivacaine to a total volume of 4.0 cc.

## EXAMPLE 2: PREPARATION OF RECOMBINANT VSV VECTORS

### A. VSV genomic cDNA cloning.

- 10 The genetic background for VSV genomic cDNA manipulation is pVSV-XN1 (Schnell, M. J., *et al* 1996 *J. Virol.*, 70:2318-23). This clone contains a modified form of the VSV Indiana strain (VSV<sub>i</sub>) cDNA sequence. The modifications include the addition of two unique restriction endonuclease recognition sites (XhoI and NheI), and added copies of VSV gene-start and VSV gene-end signals. When  
15 foreign genes such as HIV-1<sub>89.6p</sub> *env gp160* or SIV *gag p55* or HIV-1 *gag*, are conveniently inserted between the XhoI and NheI sites, they reside in a position suitable for expression controlled by VSV transcriptional control signals. Also, the VSV cDNA sequence is flanked by cis-acting DNA sequences required to promote rescue of the live virus replicates. The T7 RNA polymerase promoter directs  
20 transcription of a primary transcript across the viral cDNA. The ribozyme cleaves the primary transcript to form the end of the RNA genome after T7 RNA polymerase terminates transcription.

- Initially, the rVSV<sub>i</sub> genomic clone (pVSV-XN1) was modified by insertion of the *gag* gene (HIV Clade B) between the *G* and *L* genes to produce plasmid  
25 prVSV<sub>i</sub>-*gag*. Similarly, a separate rVSV<sub>i</sub> cDNA clone was made that contains the HIV *env* gene (genomic clone prVSV<sub>i</sub>-*env*). The *gag* and *env* cDNA sequences were prepared for insertion into pVSV-XN1 by amplifying the coding region sequences from plasmid templates that contain the HIV HXBc2 *gag* gene or HIV 6101 strain *env* gene. The primers used for PCR amplification contained terminal restriction  
30 enzyme cleavage sites appropriate for subsequent cloning; the 5' primer contained an XhoI site and the 3' primer contained an NheI site. The amplified coding region

sequences were separately inserted into pVSV-XN1 to generate a clone containing *gag* and a clone containing *env*.

5 The *env* gene inserted into pVSV-XN1 was a modified form that encodes an HIV Env/VSV G fusion protein. Cell surface expression of Env after infection with a rVSV-HIV Env vector was shown to be enhanced if the cytoplasmic tail of Env was replaced by the shorter cytoplasmic tail of the VSV G protein using an overlap PCR procedure (see, e.g., Johnson, *et al*, 1998 cited above; Johnson *et al*, 1997, cited above). The vector backbone of these two plasmids was altered by changing the Indiana *G* gene to that of the Chandipura or New Jersey serotypes according to published techniques. Exchanging *G* genes was accomplished by taking advantage of a unique MluI site in the *M* gene and the XhoI site that was engineered in the VSV cDNA clones.

VSV *G* gene coding sequences from the Chandipura strain or the New Jersey strain were PCR amplified using a 5' primer that extends across the MluI site within the *M* gene. A 3' PCR primer was used that contains sequences homologous to the 3' end of the *G* gene as well as additional terminal sequences corresponding to the gene-end/gene-start signal and the XhoI site. The *G* gene coding sequences amplified with these primers were used to replace the original Indiana *G* gene after it had been excised from the plasmid backbone with MluI and XhoI.

#### 20 **B. Rescue of rVSV from cDNA Clones**

The genomic cDNA plasmid or RNA transcribed from a genomic cDNA plasmid was not sufficient to initiate the viral replicative cycle after being introduced into a cell. By itself, viral genomic RNA was not an active template for translation or replication. Thus, recombinant virus must be recovered from the various VSV genomic cDNA constructs. Rescue procedures known in the art have made it possible to recover virus from cloned DNAs. Successful virus rescue required that VSV genomic RNA was present in the cell along with VSV N protein to encapsidate the viral genomic RNA, as well as P and L proteins, which form the viral RNA-dependent RNA polymerase needed for viral mRNA synthesis and genome replication. Producing all of these viral components within cultured cells was accomplished by cotransfecting plasmids for the VSV genomic cDNA plus expression plasmids that encode VSV N, P and L proteins.

All of these plasmids were designed for transcription by phage T7 RNA polymerase; accordingly transfected cells were also infected with a recombinant vaccinia virus that expresses the phage polymerase (MVA/T7 or VTF7-3). The standard procedure used for VSV rescue is described in Lawson *et al.* 1995, cited  
5 above; and Schnell *et al.*, 1996 *J. Virol.*, 70:2318-23. This procedure was modified to make it more efficient for rescue of highly attenuated viruses, and also to make the procedure consistent with regulatory agency guidelines. Briefly, the method is described below.

Qualified Vero cells in 12.5 cm<sup>2</sup> flasks were transfected with a rVSV  
10 genomic clone and supported plasmids encoding the VSV *N*, *P* and *L* genes using a calcium-phosphate transfection procedure. At the time transfection was initiated, enough certified MVA/T7 was added to provide a multiplicity of infection of 2 plaque-forming units per cell. Three hours after the start of transfection, the cells were subjected to a 3 hour heat shock step to improve rescue efficiency of several  
15 negative strand RNA viruses (Parks, C. L. et al, 1999 *J. Virol.*, 73:3560-6). At 48-72 hours after transfection, the cells and culture medium were transferred to a larger flask containing an established monolayer of Vero cells and subsequently incubated one or more days to allow amplification of rescued virus. Virus harvested after this amplification step was filtered to remove most contaminating MVA/T7, and used for  
20 clonal isolation of a rVSV strain.

The nucleotide sequence of the viral genomic RNA was determined by a consensus sequencing method to analyze RNA viral genomes. Briefly, purified viral RNA was reverse transcribed to produce cDNA, and then overlapping regions of the genome were amplified by PCR using gene-specific primers. PCR products were gel  
25 purified, then subjected to cycle-sequencing using fluorescent dye-terminators. Sequencing reaction products were purified and analyzed on an automated sequencer.

### **C. Specific Constructs Used in the Examples**

To produce the specific recombinant VSV vectors used in the following experiments, recombinant VSVs expressing the HIV-1 89.6P gp160 fused to the  
30 transmembrane region of the VSV G protein (rVSV HIV-1envG) and SIVmac239 gag p55 (rVSV SIVgag) were mixed and used as the experimental immunogenic composition. A rVSV expressing the influenza hemagglutinin protein (rVSV fluHA)

was used as a control composition. Recombinant VSV vectors were prepared as previously described (Rose *et al*, 2000 *J. Virol.* 74:10903-10) with the gene encoding the desired antigen inserted between the VSV G and L transcription units. The following construction was described in Rose *et al*, *supra*.

5                   1.       **Plasmid construction.**

A plasmid containing the Chandipura glycoprotein [G(Ch)] gene (Masters, P. S., 1989 *Virol.*, 171:285-290) was kindly provided by Dr. Amiya Banerjee, Cleveland Clinic. To construct the VSV vector containing the G(Ch) gene in place of the Indiana glycoprotein [G(I)] gene, an *XhoI* site was first removed from  
10       within the G(Ch) gene using oligonucleotide-directed mutagenesis with the complementary primers 5'-CCCCTAGTGGGATCTCCAGTGATATTTGGAC (SEQ ID NO: 2) and 5'-GTCCAAATATCACTGGAGATCCCACTAGGGG (SEQ ID NO: 3) and the Stratagene QuikChange mutagenesis kit. The mutation of CTCGAG (SEQ ID NO: 4) to CTCCAG (SEQ ID NO: 5) eliminated the *XhoI* site  
15       without affecting the amino acid sequence of the G(Ch) protein. The gene was then amplified by PCR using Vent DNA polymerase (New England Biolabs). The forward primer was 5'-GATCGATCGAATTCACGCGTAACATGACTTCTTCAG (SEQ ID NO: 6), containing an *MluI* site (underlined) upstream of the ATG initiation codon for the G(Ch) protein. The reverse primer was 5'-GAACGGTCGACGCGCC  
20       TCGAGCGTGATATCTGTTAGTTTTTTCATATCATGTTGTTGGGCTTG AAGATC (SEQ ID NO: 7) and contained *SalI* and *XhoI* sites (bold), followed by VSV transcription start and stop signals (underlined), followed by the complement of the 3' coding sequence of G(Ch).

The PCR product was digested with *MluI* and *SalI* and cloned into the  
25       pVSVXN-1 vector (Schnell, *et al* 1996 *J. Virol.* 70:2318-2323) that had been digested with *MluI* and *XhoI* to remove the VSV G(I) coding sequence (*SalI* and *XhoI* leave compatible ends for ligation). The plasmid derived by this method was designated pVSV(GCh)XN-1 and contains an expression site for foreign genes flanked by unique *XhoI* and *NheI* sites between the G(Ch) gene and the L gene.

30       A procedure identical to that described above was used to generate the vector containing the G(NJ) protein gene from plasmid pNJG (Gallione, C. J., and J. K.

Rose. 1983 *J. Virol.* 46:162-169). The forward primer was 5'-GATCGATCGAA TTCACGCGTAATATGTTGTCTTATCTAATCTTTGC (SEQ ID NO: 8), and the reverse primer was 5'-GGAACGGTCTGACGCGCCTCGAGCGTGATATCTGTT AGTTTTTTCATATTAACGGAAATGAGCCATTTCACG (SEQ ID NO: 9).

5 The sites indicated by bold letters and the underlined sequences are as described for the Chandipura construction above, and the subsequent cloning steps were also as described above. The final vector plasmid derived was designated pVSV(GNJ)XN-1 and contains an expression site for foreign genes flanked by unique *XhoI* and *NheI* sites between the *G(NJ)* gene and the VSV *L* gene.

10 To generate the vectors containing the HIV *Env* 89.6 *G* gene, the gene encoding the 89.6 envelope protein with the VSV *G* cytoplasmic tail was excised with *XhoI* and *NheI* from pVSV-89.6gp160G (Johnson *et al* 1997, cited above) and cloned between the *XhoI* and *NheI* sites in vector pVSV(GNJ)XN-1 or pVSV(GCh)XN-1. This *gp160G* gene encodes all of gp120 and the ecto- and  
15 transmembrane domains of gp41 and has four amino acids of the 89.6 Env cytoplasmic domain (N-R-V-R) (SEQ ID NO: 10) fused to the 26 C-terminal amino acids of the VSV *G* cytoplasmic domain, beginning with the sequence I-H-L-C (SEQ ID NO: 11).

## 2. Recoveries of recombinant viruses.

20 Recombinant VSVs were recovered using established methods (Lawson *et al* 1995 cited above). Briefly, baby hamster kidney (BHK) cells were grown to approximately 60% confluency on 10-cm dishes. The cells were then infected at a multiplicity of infection (MOI) of 10 with vTF7-3, a recombinant vaccinia virus that expresses T7 RNA polymerase (Fuerst *et al* 1987 *Mol. Cell. Biol.* 7:2538-2544). After 1 hour, each dish of cells was transfected with 3 µg of pBS-N, 5  
25 µg of pBS-P, 1 µg of pBS-L, and 10 µg of the plasmid encoding one of the three full-length recombinants described above. Transfections were performed with a cationic liposome reagent containing dimethyldioctadecyl ammonium bromide and dioleoyl-phosphatidylethanolamine (Rose *et al*, 1991 *Biotechniques* 10:520-525). Cells were  
30 then incubated at 37°C for 48 hours. Cell supernatants were passed through a 0.2-µm filter to remove the majority of the vaccinia virus and then applied to fresh BHK cells for an additional 48 hours at 37°C. For some recoveries, an additional plasmid

encoding VSV G (pBS-G), 4 µg/plate, was included with the N, P, and L support plasmids. Recovery of infectious virus was confirmed by scanning BHK cell monolayers for VSV cytopathic effect. Virus plaques were then isolated on BHK cells, and virus stocks from individual plaques were grown by adding virus from a single plaque to a 10-cm-diameter plate of BHK cells. These stocks were then stored at 80°C. The titers obtained for VSV(GI)-89.6G, VSV(GCh)-89.6G, and VSV(GNJ)-89.6G were all in the range of  $10^7$  to  $10^8$  PFU/ml after freezing and thawing, a procedure that reduces VSV titers approximately threefold.

For use in the following experiments, each rVSV construct was diluted to a final volume of 0.8cc with sterile DME.

### EXAMPLE 3: PRIME/BOOST IMMUNIZATION REGIMEN

#### A. Immunization Protocols

Rhesus macaques (5 per group) were immunized by intramuscular injection with 5 mgs of a bicistronic DNA plasmid encoding rhesus IL-12 p35 and IL-12 p40 in combination with 5 mgs of a DNA plasmid expressing SIV gag p37 polyprotein (Groups 1 and 2), or 10 mgs of an empty DNA plasmids (Groups 3 and 4). All these DNA plasmids and the formulations thereof are described in detail in Example 1. The DNA immunization schedule provided for an initial immunization at day 0, followed by a first and second booster immunization at week 4 and week 8. The injections were made at four sites in the deltoids and quadriceps with 1cc per site using a needle and syringe.

The macaques were then boosted at week 15 by intranasal inoculation (0.4 cc/nostril with handheld pipetter) with either the recombinant vesicular stomatitis virus (rVSV) of serotype Indiana (I) based vector of Example 2 containing HIV-1 *gp160 env* gene ( $5 \times 10^6$  pfu) and a second rVSV(I) containing SIVgag *p55* gene ( $5 \times 10^6$  pfu) (Groups 2 and 3), or rVSV(I) containing influenza hemagglutinin gene ( $1 \times 10^7$  pfu) (Groups 1 and 4). The macaques were again boosted at week 23 by intranasal inoculation (0.4 cc/nostril with handheld pipetter) with either the rVSV (serotype Chandipuri, Ch) based vector of Example 2 containing HIV-1 *gp160 env* gene ( $5 \times 10^6$  pfu) and a second rVSV(Ch) containing SIVgag *p55* gene ( $5 \times 10^6$  pfu)

(Groups 2 and 3), or rVSV(Ch) containing influenza hemagglutinin gene ( $1 \times 10^7$  pfu) (Groups 1 and 4).

5 Macaques were closely monitored for the induction of cellular and humoral immune responses in peripheral blood and for antibody responses at various mucosal surfaces. This monitoring involved the performance of the enzyme-linked immunospot assay (ELISpot) for SIV gag p55 peptide pool for gamma interferon, an ELISpot for HIV-1 env 6101 peptide pool for gamma interferon and an ELISpot for VSV N peptide pool for gamma interferon. The ELISpot assay detected cellular immune responses in the PBL.

10 Humoral immune responses are examined by evaluating the serum (FIG. 4), nasal wash, rectal secretions and saliva (data not shown) for anti-SIV gag p27 IgG titers by ELISA and anti-HIV-1 gp160 env titers by ELISA (data not shown). For the serum, the antibodies employed in the ELISA were normal antibodies to the chimeric viruses SHIV89.6 and SHIV89.

15 **B. *ELISpot Assay to detect cytokine-secreting murine and human cells***

The filter immunoplaque assay, otherwise called the enzyme-linked immunospot assay (ELISpot), was initially developed to detect and quantitate individual antibody-secreting B cells. The technique originally provided a rapid and versatile alternative to conventional plaque-forming cell assays. Recent modifications  
20 have improved the sensitivity of the ELISpot assay such that cells producing as few as 100 molecules of specific protein per second can be detected. These assays take advantage of the relatively high concentration of a given protein (such as a cytokine) in the environment immediately surrounding the protein-secreting cell. These cell products are captured and detected using high-affinity antibodies.

25 The ELISpot assay utilizes two high-affinity cytokine-specific antibodies directed against different epitopes on the same cytokine molecule: either two monoclonal antibodies or a combination of one monoclonal antibody and one polyvalent antiserum. ELISpot generates spots based on a colorimetric reaction that detects the cytokine secreted by a single cell. The spot represents a "footprint" of the original cytokine-producing cell. Spots (i.e., spot forming cells or SFC) are  
30 permanent and can be quantitated visually, microscopically, or electronically.



The ELISpot assay was performed as follows: Ninety-six-well flat-bottom ELISpot plates (Millipore, Bedford, MA) were coated overnight with a mouse anti-human  $\gamma$  interferon (hIFN- $\gamma$ ) monoclonal antibody (clone 27, BD-Pharmingen, San Diego CA) at a concentration of 1  $\mu\text{g/mL}$ , washed ten times with 1x PBS supplemented with 0.25% Tween-20, and blocked for 2 hours with PBS containing 5% fetal bovine serum (FBS). Rhesus macaque peripheral blood lymphocytes (PBLs) were isolated from freshly drawn heparinized whole blood by Ficoll-Hypaque density gradient centrifugation and resuspended in complete culture medium (RPMI 1640 medium supplemented with 5% FCS, 2 mM L-glutamine, 100 units/mL penicillin, 100  $\mu\text{g/mL}$  streptomycin sulfate, 1 mM sodium pyruvate, 1 mM HEPES, 100  $\mu\text{M}$  non-essential amino acids) containing either 50  $\mu\text{g/mL}$  PHA-M (Sigma), a pool of 15 amino acid peptides overlapping by 11 amino acids spanning the entire SIV gag open reading frame (1  $\mu\text{M}$  final peptide concentration), or medium alone.

Input cell numbers were  $2 \times 10^5$  PBLs in 100  $\mu\text{L}$ /well and assayed in duplicate wells. Cells were incubated for 16 hours at 37°C and then removed from the plate by washing first with deionized water and then 10 times with 1x PBS containing 0.25% Tween-20. Thereafter, the plates were treated with a rabbit polyclonal anti-hIFN- $\gamma$  biotinylated detector antibody (0.2  $\mu\text{g}$ /well, Biosource, Camarillo, CA) diluted with 1x PBS containing 1% BSA and incubated at room temperature for 2 hours. Plates were then washed 10 times with 1x PBS containing 0.25% Tween-20 and treated with 100  $\mu\text{L}$  per well of streptavidin-alkaline phosphatase conjugate (Southern Biotech, Birmingham AL) diluted 1:500 with 1x PBS containing 5% FBS and 0.005% Tween-20 and incubated an additional 2.5 hours at room temperature. Unbound conjugate was removed by rinsing the plate 10 times with 1x PBS containing 0.25% Tween-20. Chromogenic substrate (100  $\mu\text{L}$ /well, 1-step NBT/BCIP, Pierce, Rockford, IL) was then added for 3-5 minutes, rinsed away with water, the plate air-dried, and resulting spots were counted by eye using an inverted dissecting microscope.

The performance of the ELISpot assay to the present invention measured the number of CD8+ T cells (CTLs) and CD4+ T cells induced in response to the prime/boost immunization method of this invention, as measured by the production

of gamma interferon. This assessment was tracked through week 25 for the above-treated macaques (after 3 DNA primes and 2 VSV boosts).

### C. Results

After primary DNA immunization, SIVgag-specific IFN- $\gamma$  ELISpot responses were readily detected in 8 of 10 SIV gag/rIL-12 DNA immunized macaques (mean 254 SFC/ $10^6$  cells). After the second SIV gag/IL-12 DNA immunization, 10 of 10 immunized macaques developed high level ELISpot responses (mean 1133 SFC/ $10^6$  cells) and a third dose of gag/IL-12 DNA boosted the gag-specific ELISpot responses in a majority of animals (mean 1506 SFC/ $10^6$  cells). After the first rVSV HIVenv/rVSV SIVgag boost, mean SIV gag ELISpot responses were substantially higher (3772 SFC/ $10^6$  cells) than responses receiving only a single rVSV HIVenv/rVSV SIVgag immunization (mean 386 SFC/ $10^6$  cells). These results support the use of a cytokine enhanced DNA prime to augment the immunogenicity of rVSV immunization.

These results are reported in Table 1 below and in FIGs. 2, 3, 4 and 5. FIG. 2 shows the rVSV N-specific IFN- $\gamma$  ELISpot responses in unfractionated peripheral blood mononuclear cells (PBMC) from these animals immunized after week 25. FIG. 3 shows the HIVenv 6101-specific IFN- $\gamma$  ELISpot responses for the same samples. Asterisks indicate where statistically significant differences occurred at  $p=0-.0001$ . FIG. 4 shows the results of the serum antibody responses measuring anti-SIV gag p27 IgG titers by ELISA and anti-HIV-1gp160 env titers by ELISA. A protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing flu HA protein is represented by ( $\blacklozenge$ ). A protocol of the invention involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins is represented by ( $\blacksquare$ ). A protocol involving a priming immunization with an empty control DNA followed by immunization with a VSV expressing the HIV gag and env proteins is represented by ( $\blacktriangle$ ). A protocol involving a priming immunization with control DNA plasmid followed by immunization with a VSV expressing flu HA protein is represented by ( $\bullet$ ). Each group represents results from 5 animals. Statistically significant differences between groups are shown as  $p=0.0073$  (\*);  $p=0.5941$  (#) or  $p=0.0027$  ( $\neq$ ).

FIG. 5 shows the mean SIV gag-specific IFN- $\gamma$  ELISpot responses for the same samples. A protocol of immunization with the DNA plasmid encoding the SIV gag protein with a boost of a VSV vector expressing flu HA protein is represented by ( $\diamond$ ). A protocol of the invention involving a priming DNA gag plasmid immunization followed by a VSV boost expressing the HIV gag and env proteins is represented by ( $\blacksquare$ ). A protocol involving a priming immunization with an empty control DNA followed by immunization with a VSV expressing the HIV gag and env proteins is represented by ( $\blacktriangle$ ). The ( $\bullet$ ) represent a protocol involving a priming immunization with control DNA plasmid followed by immunization with a VSV expressing flu HA protein. Each group represents results from 5 animals. Statistically significant differences between groups are indicated by brackets for  $p=0.0001$  and  $p=0.0002$ .

Table 1 reports the same results in tabular form.

Table 1: Mean SIV gag-specific IFN-gamma ELISpot responses in rhesus macaques following a SIV gag/rhesus IL-12 DNA prime and a rVSV-SIVgag/rVSV-HIVenv boost

Group #/Protocol/ No. of Animals	Prime	Boost	Mean SIVgag-specific IFN $\gamma$ ELISpot response (#SFC/10 <sup>6</sup> PBLs) <sup>a</sup>
1, prime only (n=5)	SIVgag/IL-12 DNA	VSV FluHA	471
2, prime/boost (n=5)	SIVgag/IL-12 DNA	VSV-SIVgag/HIVenv	2,338
3, boost only (n=5)	empty DNA	VSV-SIVgag/HIVenv	420
4, control (n=5)	empty DNA	VSV FluHA	55

<sup>a</sup> mean SIV gag-specific ELISpot responses are reported at week 25 after the initial DNA immunization.

The results of these assays demonstrate a surprising synergistic effect of a prime/boost regimen according to this invention, when compared to the results of administering multiple priming compositions only and multiple boosting compositions only. The combination of the presentation of the desired antigen by a DNA plasmid administration followed by a rVSV boost produces an increase in antigen-specific T cells in the immunized subject, that is considerably in excess of

any additive response. Similarly, the increase demonstrated in the humoral response to the desired antigen is unexpectedly high with the use of both the DNA plasmid and rVSV immunogenic compositions in an immunization protocol.

5      EXAMPLE 4: MACAQUE MODEL FOR IMMUNIZATION AGAINST HIV

Rhesus (Rh) macaques are immunized using the prime/boost strategy of Example 3 and the plasmids and VSV vectors described therein according to the same protocols. About 32 weeks after the first priming composition administration, the macaques are challenged with a dose of 330 50% monkey infectious doses  
10      (MID<sub>50</sub>) of pathogenic SIV/HIV recombinant virus SHIV89.6P (Reimann *et al*, 1996 *J. Virol.*, 70:3198-3206; Reimann *et al* 1996 *J. Virol.*, 70:6922-6928).

About 50-70 days following challenge, the animals are monitored for disease. Animals are monitored for the induction of cell-mediated and antibody responses immediately prior to, and one and two weeks after each immunization. Serum  
15      collected prior to challenge and 2, 4, 6, 8 and 12 weeks after challenge is tested for neutralizing antibody responses against HIV-1 89.6, 89.6P, 6101 and other Clade B primary isolates. During the immunization phase of the experiment, immediately prior to and every two weeks after challenge, CD4/CD8 counts are monitored. Immediately before and every week after challenge, viral loads in serum are  
20      determined by branch DNA analysis. Other body fluids (vaginal, rectal, and nasal secretions, as well as saliva) of the animals are examined for cellular and humoral immune responses.

Cell-mediated immune responses to the desired antigen are analyzed using several of the most appropriate cell based assays, which include the <sup>51</sup>Cr-release CTL  
25      assay, soluble MHC Class I tetramer staining, ELISpot assay, and intracellular cytokine analysis. Mucosal antibody responses are evaluated by ELISA techniques optimized for use with mucosal samples. Serum antibody responses are evaluated by standard ELISA techniques. In addition, serum from all immunized animals is examined for neutralization antibody responses against HIV Env 6101 and other  
30      primary Clade B isolates. FIG. 6 illustrates that the elevated immune responses elicited by the prime/boost combinations of this invention result in increased

protection from AIDS, as measured by a decreased loss of CD4 T-cells cells for at least 250 days post-challenge.

In addition to monitoring immune responses elicited by the immunogenic composition, the live virus vector's transmission potential is assessed by determining the level and duration for which it is shed. Nasal washes obtained at frequent intervals during the first three weeks after each immunization are tested for the presence of live VSV. Plasma viral load is also examined for the presence of live virus copies. FIG. 7 demonstrates that the elevated immune responses elicited by the prime/boost combinations result in a decrease in circulating virus in plasma for at least 250 days post-challenge.

The results of such examinations are also likely to be very high antigen-specific CD8+ and CD4+ T cells in the animals immunized according to this invention in contrast with control animals. It is anticipated that animals immunized according to the prime/boost methodology of this invention will remain healthy after HIV exposure, while unimmunized animals will develop AIDS.

A comparison of the results of this protocol with other known prime/boost methodologies is anticipated to demonstrate that the method of the present invention has advantages in safety for the immunized animals and in eliciting higher levels of anti-HIV CTLs and antibodies than provided by immunization with the one or multiple DNA priming composition immunizations alone or with one or multiple rVSV vector immunizations alone. Repeated prime/boost according to this invention is likely to be synergistic and thus both prophylactically beneficial to pre-exposed subjects and therapeutically beneficial to subjects already infected with HIV.

All documents cited in the specification above are incorporated herein by reference. Various modifications and minor alterations in the method and components are believed to be clear to those of skill in the art.